Skip to content
POM-V Prescription Required Companion Animal

Versican Plus DHPPi/L4R Lyophilisate and Suspension for Suspension for Injection for Dogs

Active ingredients: Canine adenovirus, Canine distemper virus, Canine parainfluenza virus, Canine parvovirus, Leptospira interrogans serogroup Australis, Leptospira interrogans serogroup Canicola, Leptospira interrogans serogroup Icterohaemorrhagiae, Leptospira kirschneri serogroup Grippotyphosa, Rabies virus

Form

Injection

Species

Dogs

Manufacturer

Zoetis UK Limited

VMD MA No.

42058/5081

What it's used for

Active immunisation of dogs from 8–9 weeks of age: - to prevent mortality and clinical signs caused by canine distemper virus, - to prevent mortality and c...

Full indications, dosage and side effects ↓
View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Canine adenovirus + Canine d...

  1. 1

    Ask your vet for a written prescription

    They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.

  2. 2

    Fill it at a registered online retailer

    The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Versican Plus DHPPi/L4R Lyophilisate and Suspension for Suspension for Injection for Dogs — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 26 Mar 2026.

Active immunisation of dogs from 8–9 weeks of age:
- to prevent mortality and clinical signs caused by canine distemper virus,
- to prevent mortality and clinical signs caused by canine adenovirus type 1,
- to prevent clinical signs and reduce viral excretion caused by canine adenovirus
type 2,
- to prevent clinical signs, leucopoenia and viral excretion caused by canine
parvovirus,
- to prevent clinical signs (nasal and ocular discharge) and reduce viral excretion
caused by canine parainfluenza virus,
- to prevent clinical signs, infection and urinary excretion caused by L.
interrogans serogroup Australis serovar Bratislava,
- to prevent clinical signs and urinary excretion and reduce infection caused by L.
interrogans serogroup Canicola serovar Canicola and L. interrogans serogroup
Icterohaemorrhagiae serovar Icterohaemorrhagiae,
- to prevent clinical signs and reduce infection and urinary excretion caused by L.
kirschneri serogroup Grippotyphosa serovar Grippotyphosa and
- to prevent mortality, clinical signs and infection caused by rabies virus.
Onset of immunity:
- 2 weeks after a single vaccination from 12 weeks of age for rabies,
- 3 weeks after the first vaccination for CDV, CAV, CPV,
- 3 weeks after completion of the primary course for CPiV and
- 4 weeks after completion of the primary course for components.
Duration of immunity:
At least three years following the primary vaccination course for canine distemper
virus, canine adenovirus type 1, canine adenovirus type 2, canine parvovirus and
rabies. The duration of immunity against CAV-2 was not established by challenge. It
was shown that 3 years after the vaccination CAV-2 antibodies are still present.
Protective immune response against CAV-2 associated respiratory disease is
considered to last at least 3 years.
At least one year following the primary vaccination course for canine parainfluenza
virus and components. Duration of immunity for rabies was demonstrated
after one vaccination at 12 weeks of age.
None.
Dogs:
Common
(1 to 10 animals / 100 animals
treated):
injection site swelling
Rare
(1 to 10 animals / 10,000 animals
treated):
hypersensitivity reaction
(anaphylaxis,
angioedema, circulatory shock, collapse,
diarrhoea, dyspnoea, vomiting)
anorexia, decreased activity
Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
hyperthermia, lethargy, malaise
immune mediated haemolytic anaemia,
immune mediated haemolytic
thrombocytopenia, immune mediated
polyarthritis
A transient swelling (up to 5 cm) which can be painful, warm or reddened. Any such
swelling will either have spontaneously resolved or be greatly diminished by 14 days
after vaccination.
If a hypersensitivity reaction occurs, appropriate treatment should be administered
without delay. Such reactions may evolve to a more severe condition which may be
life-threatening.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See also the last section of the
package leaflet for respective contact details.
A good immune response is reliant on a fully competent immune system.
Immunocompetence of the animal may be compromised by a variety of factors

Revised: August 2023
AN: 01453/2022
including poor health, nutritional status, genetic factors, concurrent drug therapy and
stress.
Immunological responses to the CDV, CAV and CPV components of the vaccine may
be delayed due to maternally derived antibody interference. However, the vaccine
has been proven to be protective against virulent challenge in the presence of
maternally derived antibodies to CDV, CAV and CPV at levels equal or higher to
those likely to be encountered under field conditions. In situations where very high
maternally derived antibody levels are expected, the vaccination protocol should be
planned accordingly.
Vaccinate healthy animals only.

i) Special precautions for use in animals
Do not use in animals that are showing signs of rabies or that are suspected of being
infected with rabies virus.
The live attenuated virus vaccine strains CAV-2, CPiV and CPV-2b may be shed by
vaccinated dogs following vaccination, shedding of CPV has been shown for up to 10
days. However, due to the low pathogenicity of these strains, it is not necessary to
keep vaccinated dogs separated from non-vaccinated dogs and domestic cats. The
vaccine virus strain CPV-2b has not been tested in other carnivores (except dogs
and domestic cats) that are known to be susceptible to canine parvoviruses and
therefore vaccinated dogs should be separated from them after vaccination.
ii) Special precautions to be taken by the person administering the veterinary
medicinal product to animals
In case of accidental self-injection, seek medical advice immediately and show the
package leaflet or the label to the physician.
Special precautions for the protection of the environment:
Not applicable.
iii) Other precautions
Not applicable.

Revised: August 2023
AN: 01453/2022
No information is available on the safety and efficacy of this vaccine when used with
any other veterinary medicinal product. A decision to use this vaccine before or after
any other veterinary medicinal product therefore needs to be made on a case by
case basis.
Store and transport refrigerated (2 °C – 8 °C).
Do not freeze.
Protect from light.
TCID50*
Canine adenovirus Type 2, strain CAV-2 Bio 13 10
3.6
TCID50* 10
5.3
TCID50*
Canine parvovirus Type 2b, strain CPV-2b Bio 12/B 10
4.3
TCID50* 10

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.

Medication costs adding up?

Pet insurance can cover prescription medications. Find the right policy for your pet.

Compare insurance

Find cheaper vets near you

Compare vet consultation prices in your area. Save on procedures and get a prescription to buy medications online.